Zhejiang Tianyu Pharmaceutical Co Ltd Total Assets
Zhejiang Tianyu Pharmaceutical Co Ltd total assets. Based on the latest financial reports, Zhejiang Tianyu Pharmaceutical Co Ltd (300702) holds total assets worth CN¥6.89 Billion CNY (≈ $1.01 Billion USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see 300702 market cap for the company's overall valuation and market capitalisation.
Total Assets of Zhejiang Tianyu Pharmaceutical Co Ltd (2013–2025)
Total assets of Zhejiang Tianyu Pharmaceutical Co Ltd from 2013 to 2025. This chart illustrates how Zhejiang Tianyu Pharmaceutical Co Ltd's total assets have evolved over time, based on quarterly financial data. See Zhejiang Tianyu Pharmaceutical Co Ltd (300702) share price today for real-time trading data and today's change.
Zhejiang Tianyu Pharmaceutical Co Ltd - Asset Composition Analysis
Zhejiang Tianyu Pharmaceutical Co Ltd Total Assets Breakdown (December 2025)
Zhejiang Tianyu Pharmaceutical Co Ltd total assets breakdown as of December 2025. Zhejiang Tianyu Pharmaceutical Co Ltd's total assets of CN¥6.89 Billion consist of 45.7% current assets and 54.3% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 7.8% |
| Accounts Receivable | CN¥556.85 Million | 8.5% |
| Inventory | CN¥1.71 Billion | 26.0% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥491.69 Million | 7.5% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2013–2025)
This chart illustrates how Zhejiang Tianyu Pharmaceutical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Zhejiang Tianyu Pharmaceutical Co Ltd short-term liquidity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Zhejiang Tianyu Pharmaceutical Co Ltd's current assets represent 45.7% of total assets in 2025, a decrease from 52.0% in 2013.
- Cash Position: Cash and equivalents constituted 7.8% of total assets in 2025, down from 11.3% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 7.0% of total assets, an increase from 5.0% in 2013.
- Asset Diversification: The largest asset category is inventory at 26.0% of total assets.
Zhejiang Tianyu Pharmaceutical Co Ltd Competitors by Total Assets
Key competitors of Zhejiang Tianyu Pharmaceutical Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262
|
China | CN¥9.54 Billion |
|
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211
|
China | CN¥6.44 Billion |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
|
China | CN¥1.54 Billion |
|
Renhe Pharmacy Co Ltd
SHE:000650
|
China | CN¥7.93 Billion |
|
Bide Pharmatech Co. Ltd. A
SHG:688073
|
China | CN¥2.54 Billion |
|
Jianmin Pharmaceutical Group Co Ltd
SHG:600976
|
China | CN¥4.69 Billion |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365
|
China | CN¥2.26 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥25.73 Billion |
Zhejiang Tianyu Pharmaceutical Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.12 | 1.15 | 1.69 |
| Quick Ratio | 0.57 | 0.47 | 0.84 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥327.08 Million | CN¥401.20 Million | CN¥1.13 Billion |
Zhejiang Tianyu Pharmaceutical Co Ltd - Advanced Valuation Insights
This section examines the relationship between Zhejiang Tianyu Pharmaceutical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.04 |
| Latest Market Cap to Assets Ratio | 0.16 |
| Asset Growth Rate (YoY) | 0.2% |
| Total Assets | CN¥6.59 Billion |
| Market Capitalization | $1.04 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Zhejiang Tianyu Pharmaceutical Co Ltd's assets below their book value (0.16x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Zhejiang Tianyu Pharmaceutical Co Ltd's assets grew by 0.2% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Zhejiang Tianyu Pharmaceutical Co Ltd (2013–2025)
The table below shows the annual total assets of Zhejiang Tianyu Pharmaceutical Co Ltd from 2013 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥6.59 Billion ≈ $964.21 Million |
+0.16% |
| 2024-12-31 | CN¥6.58 Billion ≈ $962.65 Million |
+3.79% |
| 2023-12-31 | CN¥6.34 Billion ≈ $927.47 Million |
-1.21% |
| 2022-12-31 | CN¥6.42 Billion ≈ $938.83 Million |
+10.60% |
| 2021-12-31 | CN¥5.80 Billion ≈ $848.81 Million |
+18.63% |
| 2020-12-31 | CN¥4.89 Billion ≈ $715.50 Million |
+72.15% |
| 2019-12-31 | CN¥2.84 Billion ≈ $415.61 Million |
+8.02% |
| 2018-12-31 | CN¥2.63 Billion ≈ $384.75 Million |
+24.81% |
| 2017-12-31 | CN¥2.11 Billion ≈ $308.27 Million |
+39.05% |
| 2016-12-31 | CN¥1.52 Billion ≈ $221.70 Million |
+14.23% |
| 2015-12-31 | CN¥1.33 Billion ≈ $194.09 Million |
+22.26% |
| 2014-12-31 | CN¥1.08 Billion ≈ $158.75 Million |
+11.64% |
| 2013-12-31 | CN¥971.79 Million ≈ $142.20 Million |
-- |
About Zhejiang Tianyu Pharmaceutical Co Ltd
Zhejiang Tianyu Pharmaceutical Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical intermediates and APIs in China and internationally. The company offers pharmaceutical intermediates and APIs of anti-hypertensive, anti-allergic, anticancer, anti-fungal, anti-epileptic, anti-asthmatic, hypoglycemic, hypolipidemic, and anticoagulant series. It also provides fine… Read more